A Research Reboot of Tuberculosis on the Keystone Symposia 50th Anniversary

摘要 请求为题为《结核病研究重启》的Keystone专题讨论会提供支助 Keystone研讨会50周年，由Joseph Keane博士、Shabaana A.Khader、Thomas J. 斯克里巴和艾伦·谢尔。大会将于2022年1月23日至26日在科罗拉多州布雷肯里奇举行。 结核病(TB)是一种古老的人类祸害，至今仍是由一种 单一病原体的全球死亡率仅次于目前的新冠肺炎冠状病毒大流行。 然而，随着有效抗生素的出现和改进的公共卫生措施，在中期 在20世纪初，结核病大幅下降，许多人认为它注定会被根除。到了1972年， 在Keystone研讨会成立的那一年，这一结论被#年扩大案件量所推翻。 纽约市和其他城市地区后来又受到艾滋病毒合并感染的毁灭性影响。这个专业 疾病的再次出现刺激了旨在征服结核病的紧张研究的新时代。这次研讨会将 展示过去50年来结核病研究人员的杰出突破，同时强调当前 该领域的进步。还将特别关注最新的有希望的疫苗试验的结果。 改进的抗生素方案的发现和实施。本节目还将强调 在我们对宿主-病原体相互作用的基本理解方面取得了令人兴奋的进展，特别是在 免疫代谢，这导致了新的宿主定向治疗靶点的确定。主旨演讲 讲座将概述主要成就，同时探索全球结核病的现状 如病毒大流行对结核病研究和控制的影响。总而言之，该计划将推动 朝着实现我们消灭结核病的最终目标前进的领域。

ABSTRACT Support is requested for a Keystone Symposia conference entitled A Research Reboot of Tuberculosis on the Keystone Symposia 50th Anniversary, organized by Drs. Joseph Keane, Shabaana A. Khader, Thomas J. Scriba and Alan Sher. The conference will be held in Breckenridge, Colorado from January 23-26, 2022. Tuberculosis (TB) is an ancient scourge of mankind that still to this day remains a leading cause of death by a single infectious agent only surpassed in its global mortality by the current COVID-19 coronavirus pandemic. Nevertheless, with the advent of effective antibiotics and improved public health measures, in the middle of the 20th century, TB had substantially declined and was thought by many to be destined for eradication. By 1972, the year of the founding of the Keystone Symposia, this conclusion was quashed by expanding caseloads in New York City and other urban areas and later by the devastating impact of HIV-coinfection. This major disease re-emergence stimulated a new era of intense research aimed at conquering TB. This symposium will showcase the outstanding breakthroughs of TB researchers over the last 50 years, while highlighting current advances in the field. Special attention will be given to the results of the latest promising vaccine trials, as well the discovery and implementation of improved antibiotic regimens. This program will also emphasize the exciting advances in our basic understanding of the host-pathogen interaction, and in particular in the area of immunometabolism, that are leading to the identification of new host-directed treatment targets. Keynote lectures will overview the major achievements, while exploring the current state of global tuberculosis, as well as the impact of viral pandemics on tuberculosis research and control. Taken together, the program will propel the field forward toward achievement of our ultimate goal of TB eradication.